At-Home Colorectal Cancer Screening Tests Compared

At-home colorectal cancer screening tests differ in what they detect, how often they need repeating, and how easily they fit into daily life. For average-risk adults, the best choice balances those differences with a practical commitment to complete the test and any needed follow-up. A more sensitive test offers little help if the kit never gets returned.

Why colorectal cancer screening starts at 45 now, and why at-home tests matter more than before

Colorectal cancer is now the top cancer killer of adults under 50. The risk to younger adults helps explain why screening now starts at 45 rather than 50, so millions more people are now eligible. The American Cancer Society’s 2026 guideline update reaffirms screening from 45 through 75 for average-risk adults with a life expectancy greater than 10 years. Screening aims to find signs of disease early, when treatment may be easier.

The ACS reports that more than 20 million eligible Americans have not been screened as recommended, roughly one in three adults. Its update expands options to help close that gap, recognizing that convenient options can help people complete screening. Mayo Clinic describes at-home stool tests as simple, safe, accurate alternatives to colonoscopy for people without symptoms or high risk. With more guideline-recommended at-home choices now available, understanding their differences is the first step toward choosing one.

What each test type is actually detecting and why the biology differs

The first distinction is between detecting blood and detecting changes in cells. The guaiac fecal occult blood test, or gFOBT, chemically detects heme, a component of hemoglobin in blood. Mayo Clinic explains that it can detect bleeding from the upper or lower digestive tract, while the fecal immunochemical test, or FIT, uses antibodies to detect human hemoglobin from the lower tract. A tumor that has not yet caused detectable bleeding can escape these tests.

Multitarget stool DNA testing, or mt-sDNA, adds another signal. Cologuard looks for DNA mutations and methylation patterns, which are chemical changes to genetic material, shed by cancerous or precancerous cells. It also checks for hemoglobin in the sample. Mayo Clinic describes the DNA component as looking for “changes in the cells' genetic material”. By detecting changes in cells as well as blood, this approach can detect cancers that FIT misses.

Multitarget stool RNA testing, or mt-sRNA, also combines molecular markers with hemoglobin detection. ColoSense is the first noninvasive colorectal cancer screening test to use RNA biomarkers, which reflect active gene expression in tumor cells. That provides a view of disease activity. The ACS added this category as a recommended option in its 2026 update.

Shield detects cell-free DNA, or cfDNA, from tumors circulating in the bloodstream, so no stool sample is needed. It is an office-based test. Tumor DNA is present in much smaller quantities in blood than the DNA or RNA shed into stool, helping explain its lower sensitivity. The ACS found that blood-based tests find fewer stage I cancers and advanced precancerous lesions than stool-based tests already in use.

How the four test types compare on sensitivity, specificity, frequency, and ease of use

Sensitivity describes how well a test detects the disease it is looking for. Specificity describes how well it correctly identifies people without that disease. A test can perform strongly on one measure without leading on the other. In this comparison, stool DNA and RNA tests offer higher cancer sensitivity than FIT, but also produce more false positives. Convenience follows a different pattern, so the easiest collection method is not necessarily the strongest detector.

Of the tests that look for blood, gFOBT is the older one. The ACS recommends annual testing, and Mayo Clinic describes collection from three separate bowel movements. Preparation also involves dietary and medication restrictions, including red meat, vitamin C, NSAIDs, and blood thinners. A healthcare professional needs to guide any changes to medication. Although gFOBT has been shown to lower deaths from colorectal cancer, it has the lowest cancer sensitivity of these stool-based tests.

FIT also needs to be done every year, but the sample is easier to collect. Mayo Clinic says it takes a single stool sample, with no need to change diet or medication. FIT has higher specificity than molecular stool tests, so fewer people get false-positive results. Its cancer sensitivity is substantially lower, however, and its sensitivity for advanced precancerous lesions is moderate. Its sensitivity is limited by its reliance on detecting blood.

Stool DNA testing trades a larger collection task for a longer interval. Cologuard and Cologuard Plus require a prescription, arrive by mail, and use a full stool sample collected in a container attached to the toilet. No dietary changes are needed before collection. The ACS recommends testing every 3 years and describes high cancer sensitivity but moderate sensitivity for advanced precancerous lesions. Cologuard Plus, approved by the federal regulator in 2024 and launched in 2025, offers modestly higher cancer sensitivity and improved specificity compared with the original version.

ColoSense has the same recommended 3-year interval. The ACS describes its cancer sensitivity as high and its sensitivity for advanced precancerous lesions as moderate, comparable to stool DNA testing. Its RNA markers are not subject to age-related methylation patterns, a potential advantage for consistency across age groups, including younger adults. That does not establish superiority in everyday use. Comparative real-world data is still accumulating following its recent approval.

A blood draw may be the easiest option for someone reluctant to handle a stool sample, but the ACS recommends it only for people who decline or cannot complete preferred screening tests. Its weaker detection of early cancers and advanced precancerous lesions is the reason. The ACS expects blood-based screening to do less than stool-based tests to lower the number of people who get colorectal cancer or die from it.

What a positive result actually means — and why follow-through is the test that really counts

Does a positive result mean a person has cancer? No, but it does require a colonoscopy to find out what caused the signal. The ACS recommends timely follow-up after a positive stool or blood test, preferably within 6 months. Without that step, a positive screening result does not produce the intended clinical benefit.

Stool DNA and RNA testing give more false positives than FIT, so more people may have a colonoscopy without cancer being found. That follow-up still involves bowel preparation, sedation, time away from work, and a small but real complication risk. Higher sensitivity has a practical cost here.

A retrospective study found that more than one in ten FIT tests were unusable for screening because the samples were unsatisfactory. Getting a useful result therefore depends in part on following the kit instructions exactly, including when to send the sample back. The same attention belongs to the follow-up plan. Knowing before testing that an abnormal result needs colonoscopy removes a surprise and makes completion easier to prepare for.

Who each test is and isn't appropriate for — the risk-stratification the comparison guides often skip

These screening choices are intended for average-risk adults ages 45 to 75 who do not have symptoms. Age alone does not establish eligibility, however. Family history or prior polyps can change the conversation, and someone with elevated risk needs a clinician’s assessment. Cologuard, for example, is approved for average-risk patients. Ordering it outside that group can create both a clinical mismatch and a coverage problem.

Symptoms call for a different kind of evaluation. Mayo Clinic says people should not rely on an at-home screening test if they have blood in the stool, abdominal pain, unexplained weight loss, or changes in bowel habits. Screening looks for disease before symptoms appear, while diagnostic evaluation investigates a problem already present. For someone with symptoms or elevated risk, the next step is a clinician and a discussion of colonoscopy referral. People outside the usual screening age range also need a different conversation, and the ACS recommends no colorectal cancer screening after 85.

For eligible adults, access can shape the choice. Distance from an endoscopy facility, schedule constraints, or reluctance about sedation and bowel preparation may otherwise prevent screening altogether. The ACS frames expanded options as a way to narrow gaps among underserved, rural, and minority populations. Collecting a sample at home can mean less travel at the start. A positive result still requires access to colonoscopy, so the practical value of home testing includes having a route to follow-up.

What these tests cost out of pocket, what insurance typically covers, and where the billing surprises hide

The list price is not necessarily the patient’s bill. Without insurance, FIT costs little, but it must be paid for again each year. Cologuard and Cologuard Plus have high list prices, and Shield costs the most of the tests compared here. A longer testing interval and a higher price therefore need to be considered together. The least expensive single kit is not the only financial question.

Insurance can change that comparison considerably for eligible adults. Under ACA preventive coverage, a screening test chosen with a clinician to meet the patient’s medical needs is usually covered at no cost to the patient, so most insured average-risk adults ages 45–75 should pay nothing for the test itself. Who is eligible and how the test is ordered still matter, especially when a test meant for average-risk adults is ordered for someone with a family history or prior polyps. The Centers for Medicare & Medicaid Services granted Medicare coverage for ColoSense in June 2026, and Medicare also covers Shield.

The less obvious expense can come after a positive result. Follow-up colonoscopy billing may be handled as diagnostic, creating potential deductibles or coinsurance for patients expecting a no-cost preventive screening benefit. Coverage and coding need attention before that appointment. For Medicare patients undergoing a post-Cologuard colonoscopy, the KX modifier is a specific billing detail to confirm with the provider. Without it, the claim may trigger the full Part B deductible plus 20% coinsurance.

How to decide which test actually fits your situation

The first decision is whether this comparison applies to you, since symptoms or elevated risk call for a clinician and a colonoscopy referral discussion. For an average-risk 45-year-old who has never been screened, any guideline-recommended stool test is a meaningful starting point. FIT offers a low barrier to entry. Stool DNA or RNA testing has higher cancer sensitivity and is done at a 3-year interval, if collecting a larger sample and having a possible false-positive follow-up feel manageable.

Someone who prefers a simple annual sample and a lower false-positive rate may find FIT the best fit, but the yearly schedule is part of that choice. Someone who prioritizes early cancer detection may prefer Cologuard, Cologuard Plus, or ColoSense and accept the greater chance of follow-up without cancer being found. A FIT completed every year is more useful than a Cologuard kit ordered and left unused.

If stool collection is an insurmountable barrier, Shield offers another route. It is approved by the federal regulator and Medicare-covered, but the ACS positions it as a fallback for people who decline preferred tests. Whatever the choice, willingness to undergo colonoscopy after a positive result belongs in the decision from the beginning. Choose a screening plan you can complete, repeat on schedule, and follow through to an answer.